NETRIS Pharma Announces Clinical Trial Collaboration Agreement with MSD to Evaluate NP137 in Combination with KEYTRUDA® (Pembrolizumab) in Advanced Uterine and Cervical Tumors Unique NP137 mechanism targeting netrin-1 could alleviate…
NETRIS Pharma is pleased to announce that the ANR (Agence Nationale de la Recherche) allocated a 6.6 M€ grant to the RHU DEPGYN project aiming to develop new therapeutic approaches…
The President of the French Republic appointed Pr. Agnès Bernet, co-founder and CSO of NETRIS Pharma, to the highest French distinction as Knight of the Legion of Honor. The award…
NETRIS Pharma announces that ANR (Agence Nationale de la Recherche) granted the translational RHU TROY program aiming at Targeting dependence Receptors (DRs) in Oncology and hematologY. This program aims at…
NETRIS Pharma announces that Agnès Bernet – co-founder and CSO of NETRIS Pharma – received the 2015 Irène Joliot-Curie award from the French Minister of Education and Research and the…
